

Figure S1: A. Antibody titers as measured by ELISA against Spike and Nucleocapsid protein at the time of acute infection and convalescence. Significance from a paired Wilcoxon test is shown. **B.** Antibody titers against Spike and Nucleocapsid protein by vaccination status. Significance from an unpaired Wilcoxon test is shown. ns: $p > 0.05$; * - $p < 0.05$; *** - $p < 0.001$; **** - $p < 0.0001$.




Figure S2: A. Neutralizing antibody responses against a panel of pseudoviruses, as measured by the 50% neutralizing antibody titer (NT50), at the time of acute infection and convalescence against a panel of pseudoviruses. Significance from a paired Wilcoxon test is shown. **B.** Neutralizing antibody responses by the infecting variant. Significance from an unpaired Wilcoxon test is shown. ns - $p > 0.05$; * - $p < 0.05$; ** - $p < 0.01$; *** - $p < 0.001$; **** - $p < 0.0001$.




Figure S3: Neutralizing antibody responses, as measured by the 50% neutralizing antibody titer (NT50), at the time of acute infection and convalescence against a panel of pseudoviruses. Responses are stratified by the genotype of the infecting variant, the genotype of the pseudovirus, and the vaccination status of the individual. Significance from a paired Wilcoxon test is shown. ns: $p > 0.05$; * - $p < 0.05$; ** - $p < 0.01$; *** - $p < 0.001$.




Figure S4: A. Neutralizing antibody responses, as measured by the 50% neutralizing antibody titer (NT50), at the time of convalescence, in unvaccinated, vaccinated or boosted individuals, against a panel of pseudoviruses. Significance from a Wilcoxon rank-sum test is shown. **B.** Neutralizing antibody responses, as measured by the 50% neutralizing antibody titer (NT50), at the time of convalescence, in unvaccinated, vaccinated, or boosted individuals, against a panel of pseudoviruses. Significance from a Kruskal-Wallis test is shown. ns: $p > 0.05$; * - $p < 0.05$; ** - $p < 0.01$; *** - $p < 0.001$; **** - $p < 0.0001$.